Fig. 7.

Fig. 7.

Chemotherapeutic agents decrease GBM9 xenotransplant tumor burden. GBM9 xenotransplants were treated with 50 μM drug continuously between 5 and 10 dpt. (A-D′) Confocal images superimposed on bright field (anterior to the left) of two GBM9 animals at 5 dpt (A,B) and at 10 dpt after 5 days of temozolomide (TMZ) treatment (A′,B′). (C,D) Confocal images superimposed on bright field (anterior to the left) of two GBM9 animals at 5 dpt (C,D) and at 10 dpt after 5 days of bortezomib (Bort) treatment (C′,D′). (E) Quantification of tumor burden (in micrometers cubed) before treatment (5 dpt) and after 5 days of treatment (10 dpt). n=10 animals per group. *P<0.001. (F) Kaplan–Meier survival curve of animals during drug treatment (5-10 dpt) with temozolomide (dark blue line) and bortezomib (light blue line). Control DMSO treated GBM9 animals (green line) have a median survival of 8±0.6 days. Of the animals treated with TMZ, 70.8% lived until 25 days compared with 50.0% treated with bortezomib. Of the wild-type animals treated with 50 μm TMZ (dashed dark blue line) or bortezomib (dashed light blue line), 83.3 and 88.0%, respectively, survived. n=48 animals for all groups. P<0.0001 for GBM9 DMSO versus both GBM9 TMZ and GBM9 Bort. P=0.0672 for GBM9 TMZ versus GBM9 Bort. Scale bars: 100 μm.